ATE546439T1 - Heterocyclische modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb- aktivität und deren verwendung - Google Patents

Heterocyclische modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb- aktivität und deren verwendung

Info

Publication number: ATE546439T1
Authority: AT; Austria
Prior art keywords: sup; glucocorticoid receptor; activity; diseases; diabetes
Prior art date: 2005-01-13

Application number

AT06718214T

Other languages

English (en)

Inventor

Bingwei YANG

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-13

Filing date

2006-01-13

Publication date

2012-03-15

2006-01-13 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE546439T1 publication Critical patent/ATE546439T1/de

Links

102000003676 Glucocorticoid Receptors Human genes 0.000 title abstract 2
108090000079 Glucocorticoid Receptors Proteins 0.000 title abstract 2
102000003945 NF-kappa B Human genes 0.000 title abstract 2
108010057466 NF-kappa B Proteins 0.000 title abstract 2
230000000694 effects Effects 0.000 title abstract 2
208000008589 Obesity Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
206010012601 diabetes mellitus Diseases 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000002757 inflammatory effect Effects 0.000 abstract 2
235000020824 obesity Nutrition 0.000 abstract 2
208000026278 immune system disease Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
230000003637 steroidlike Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)

AT06718214T 2005-01-13 2006-01-13 Heterocyclische modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb- aktivität und deren verwendung ATE546439T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US64376005P	2005-01-13	2005-01-13
PCT/US2006/001117 WO2006076509A1 (en)	2005-01-13	2006-01-13	Heterocyclic modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof

Publications (1)

Publication Number	Publication Date
ATE546439T1 true ATE546439T1 (de)	2012-03-15

Family

ID=36228744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06718214T ATE546439T1 (de)	2005-01-13	2006-01-13	Heterocyclische modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb- aktivität und deren verwendung

Country Status (6)

Country	Link
US (1)	US7317024B2 (de)
EP (1)	EP1841750B1 (de)
JP (1)	JP2008526977A (de)
AT (1)	ATE546439T1 (de)
ES (1)	ES2381278T3 (de)
WO (1)	WO2006076509A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7625921B2 (en) *	2004-01-16	2009-12-01	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) *	2004-01-16	2008-02-05	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7605264B2 (en) *	2004-01-16	2009-10-20	Bristol-Myers Squibb Company	Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7253283B2 (en) *	2004-01-16	2007-08-07	Bristol-Myers Squibb Company	Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7569689B2 (en) *	2004-01-16	2009-08-04	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) *	2004-01-16	2007-09-25	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8034940B2 (en)	2006-08-09	2011-10-11	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2011154413A1 (en)	2010-06-07	2011-12-15	Fritz-Lipmann-Insitut E. V. Leibniz-Institut Für Altersforschung	Agent against glucocorticoid-induced osteoporosis
KR20130095772A (ko)	2010-10-05	2013-08-28	퍼듀 퍼머 엘피	나트륨 채널 차단제로서 퀴나졸린 화합물
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
KR101823488B1 (ko)	2013-10-14	2018-01-30	에자이 알앤드디 매니지먼트 가부시키가이샤	선택적으로 치환된 퀴놀린 화합물
ES2670550T3 (es)	2013-10-14	2018-05-30	Eisai R&D Management Co., Ltd.	Derivados de quinolina selectivamente sustituidos
CN114014747B (zh) *	2021-08-30	2023-12-08	海南师范大学	一种多羟基环己烯类化合物及其制备方法与应用
CN115974723B (zh) *	2022-12-27	2024-10-25	中国药科大学	甲酰胺乙撑蒽类化合物、包含其的药物组合物及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3317387A (en)	1964-05-25	1967-05-02	Du Pont	Method of reducing the severity of influenza virus infections
US3422104A (en)	1964-10-20	1969-01-14	Geigy Chem Corp	9,10-dihydro-11-amino-alkylene-9,10-ethanoanthracenes
US3517073A (en)	1967-06-13	1970-06-23	Eastman Kodak Co	Synthesis of a hydroxy group-containing polycyclic aromatic fused ring compound
US4046889A (en)	1976-02-13	1977-09-06	E. R. Squibb & Sons, Inc.	Azetidine-2-carboxylic acid derivatives
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CS198678B1 (cs)	1978-03-17	1980-06-30	Jaroslav Horyna	Způsob přípravy 9,10-dihydro-9,10-ethanoantracenových derivátů
DE2951135A1 (de)	1979-12-19	1981-06-25	Hoechst Ag, 6230 Frankfurt	Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4786646A (en)	1987-07-10	1988-11-22	Hoffmann-La Roche Inc.	Cyclopropylpropenamides
US5100889A (en)	1989-04-03	1992-03-31	E. R. Squibb & Sons, Inc.	7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
EP0405436B1 (de)	1989-06-29	1995-11-15	G.D. Searle & Co.	Stickstoff enthaltende Diheterocycloheteroethanoanthracenderivate als antipsychotische Mittel
US5055468A (en)	1989-10-30	1991-10-08	G. D. Searle & Co.	Use of bridged tricyclic amine derivatives as anti-ischemic agents
US5202486A (en)	1990-07-31	1993-04-13	E. R. Squibb & Sons, Inc.	Tetrahydroethanonaphthaleneamine derivatives
US5332820A (en)	1991-05-20	1994-07-26	E. I. Du Pont De Nemours And Company	Dibenzobicyclo(2.2.2) octane angiotensin II antagonists
WO1993016982A1 (en)	1992-02-20	1993-09-02	James Black Foundation Limited	Bicyclo[2.2.2.]octane derivatives as cholestocystokinin inhibitors
US5514683A (en)	1992-02-20	1996-05-07	James Black Foundation Limited	Bicyclo 2,2,2!octane derivatives
GB9316722D0 (en)	1993-08-12	1993-09-29	Black James Foundation	Bicyclo (2.2.2)octane derivatives
US5595872A (en)	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
GB9209628D0 (en)	1992-05-05	1992-06-17	Smithkline Beecham Plc	Compounds
EP0655053B1 (de)	1992-06-19	1997-09-03	James Black Foundation Limited	Bicyclooctan und bicycloheptan derivate
US5594016A (en)	1992-12-28	1997-01-14	Mitsubishi Chemical Corporation	Naphthalene derivatives
US5346701A (en)	1993-02-22	1994-09-13	Theratech, Inc.	Transmucosal delivery of macromolecular drugs
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5569655A (en)	1993-09-14	1996-10-29	Sterling Winthrop Inc.	Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
US5455248A (en)	1993-09-14	1995-10-03	Sterling Winthrop Inc.	Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts, and compositions and method of use thereof
US5411960A (en)	1993-12-09	1995-05-02	Bayer Aktiengesellschaft	Substituted pyrroloanthracenes and -diones
US5461054A (en)	1993-12-09	1995-10-24	Bayer Aktiengesellschaft	Anthracene-spiro-pyrrolindines
US5409932A (en)	1993-12-09	1995-04-25	Bayer Ag	Piperazine-substituted pyrroloanthracenes
US5776983A (en)	1993-12-21	1998-07-07	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5488064A (en)	1994-05-02	1996-01-30	Bristol-Myers Squibb Company	Benzo 1,3 dioxole derivatives
US5491134A (en)	1994-09-16	1996-02-13	Bristol-Myers Squibb Company	Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en)	1994-12-02	1996-07-30	Bristol-Myers Squibb Company	Aryloxypropanolamine β 3 adrenergic agonists
EP0727410A1 (de)	1995-02-08	1996-08-21	Ciba-Geigy Ag	Bisphenolesterderivate
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
US6262059B1 (en)	1995-06-07	2001-07-17	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with quinazoline derivatives
WO1997012613A1 (en)	1995-10-05	1997-04-10	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
JP2000502086A (ja)	1995-12-13	2000-02-22	ザリージェンツオブザユニバーシティオブカリフォルニア	核レセプターのリガンドおよびリガンド結合ドメイン
US5770615A (en)	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5962440A (en)	1996-05-09	1999-10-05	Bristol-Myers Squibb Company	Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en)	1996-05-10	1999-03-23	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en)	1996-05-10	1998-10-27	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
HRP970330B1 (en)	1996-07-08	2004-06-30	Bayer Ag	Cycloalkano pyridines
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
GB9713739D0 (en)	1997-06-27	1997-09-03	Karobio Ab	Thyroid receptor ligands
DE19742014A1 (de)	1997-09-24	1999-03-25	Roche Diagnostics Gmbh	Neue Tetracyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1052994A2 (de)	1998-02-02	2000-11-22	Trustees Of Tufts College	Verwendung von dipetidylpeptidasehemmer zur regulierung des glukosemetabolismus
EP1062222A1 (de)	1998-03-09	2000-12-27	Fondatech Benelux N.V.	Serin-peptidase modulatoren
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6214915B1 (en)	1998-12-10	2001-04-10	General Electric Company	Stabilized thermoplastic compositions
AU2157400A (en)	1998-12-23	2000-07-31	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
GB9828442D0 (en)	1998-12-24	1999-02-17	Karobio Ab	Novel thyroid receptor ligands and method II
FR2796641B1 (fr)	1999-07-22	2001-09-21	Aventis Pharma Sa	Nouveau procede de preparation de composes benzoperhydroisoindole
AU2002230781A1 (en)	2000-12-22	2002-07-08	Celltech R And D, Inc.	Pharmaceutical uses and synthesis of benzobicyclooctanes
TWI263640B (en)	2001-12-19	2006-10-11	Bristol Myers Squibb Co	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PT1551860E (pt)	2002-06-19	2007-02-28	Karobio Ab	Ligandos de receptores glucocorticóides para o tratamento de distúrbios metabólicos
WO2004005229A1 (en)	2002-07-08	2004-01-15	Pfizer Products Inc.	Modulators of the glucocorticoid receptor
JP2006508042A (ja)	2002-07-18	2006-03-09	ブリストル−マイヤーズ　スクイブ　カンパニー	グルココルチコイド受容体の修飾物質および方法
US7625921B2 (en)	2004-01-16	2009-12-01	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en)	2004-01-16	2009-10-20	Bristol-Myers Squibb Company	Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7569689B2 (en)	2004-01-16	2009-08-04	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en)	2004-01-16	2008-02-05	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof

2006
- 2006-01-12 US US11/330,511 patent/US7317024B2/en not_active Expired - Lifetime
- 2006-01-13 ES ES06718214T patent/ES2381278T3/es not_active Expired - Lifetime
- 2006-01-13 AT AT06718214T patent/ATE546439T1/de active
- 2006-01-13 EP EP06718214A patent/EP1841750B1/de not_active Expired - Lifetime
- 2006-01-13 JP JP2007551378A patent/JP2008526977A/ja active Pending
- 2006-01-13 WO PCT/US2006/001117 patent/WO2006076509A1/en not_active Ceased

Also Published As

Publication number	Publication date
ES2381278T3 (es)	2012-05-24
US20060154962A1 (en)	2006-07-13
JP2008526977A (ja)	2008-07-24
EP1841750A1 (de)	2007-10-10
US7317024B2 (en)	2008-01-08
EP1841750B1 (de)	2012-02-22
WO2006076509A1 (en)	2006-07-20

Publication	Publication Date	Title
PL1891029T3 (pl)	2010-06-30	Związki organiczne do leczenia stanów zapalnych lub alergicznych
SE0401971D0 (sv)	2004-08-02	Piperidne derivatives
ATE525351T1 (de)	2011-10-15	Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung
GEP20156348B (en)	2015-08-25	Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
NO20082136L (no)	2008-06-30	1,5-substituerte indol-2-yl-amidderivater
NO20081554L (no)	2008-06-02	Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
UY30500A1 (es)	2008-02-29	Compuestos de azabencimidazolilo
ATE534625T1 (de)	2011-12-15	Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung
EA200800100A1 (ru)	2008-06-30	Соединения азаиндазола и способы применения
SE0401345D0 (sv)	2004-05-25	Therapeutic compounds: Pyridine as scaffold
NO20062583L (no)	2006-09-20	Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
ATE537830T1 (de)	2012-01-15	Nicotinamid derivate und ihre verwendung als therapeutika
ATE525350T1 (de)	2011-10-15	Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung
EA200802214A1 (ru)	2009-06-30	2,4-диаминопиримидины в качестве ингибиторов киназ, участвующих в регуляции клеточного цикла
EA200800081A1 (ru)	2008-06-30	Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты)
DE602006020273D1 (de)	2011-04-07	Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon
DE602005017895D1 (de)	2010-01-07	Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
PT2139334E (pt)	2013-10-02	Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
SE0401342D0 (sv)	2004-05-25	Therapeutic compounds
SE0401970D0 (sv)	2004-08-02	Novel compounds
NO20082112L (no)	2008-06-23	3-Amino-2-arylpropylazaindoler og deres anvendelse
ATE499350T1 (de)	2011-03-15	Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb-aktivität und deren verwendung
BRPI0417858A (pt)	2007-04-27	composto, composição farmacêutica, e, uso de uma composição farmacêutica
ATE478856T1 (de)	2010-09-15	Spirobenzodioxole und deren verwendung als cb1- antagonisten
ATE467632T1 (de)	2010-05-15	Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors